Scholar Rock Holding Corporation (SRRK)
Nasdaq · Healthcare · Biotechnology
$43.40−7.28%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $5.3B
- 52-week range
- $27.07 – $61.76
- 52-week change
- +17.61%
- EPS (trailing)
- −$3.08
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $0K
- Net income
- −$378M
- Diluted EPS
- −$3.29
- Free cash flow
- −$301M
From the company’s annual report on SEC EDGAR.
About Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies.
Headquarters: Cambridge, United States · 289 employees · scholarrock.com